MD Anderson, Boehringer launch virtual center for data-driven drug discovery

Houston-based MD Anderson Cancer Center and international pharmaceutical company Boehringer Ingelheim have established a Virtual Research and Development Center to accelerate research into new cancer treatments.

The center will enable data sharing and analysis for researchers from both organizations. The initiative will be led in part by the team from MD Anderson's Therapeutics Discovery division, which studies clinical data to understand how and for which patients new treatments will be most effective. Their findings will then be fed into Boehringer's existing pipeline for the development of novel medicines.

Among the collaboration's targets are treatments for mutations in the KRAS gene, commonly associated with certain types of lung and gastrointestinal cancers, and the development of an antibody with the ability to induce apoptosis.

More articles on innovation:
6 key quotes about innovation's role in healthcare
Apple Health researcher jumps ship for Gates Foundation's digital health group
The key to successful innovation? 'The art of noticing'

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers